Giulio Antonelli
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Giulio Antonelli.
Annals of Hepatology | 2017
Paola Begini; Elia Gigante; Giulio Antonelli; Francesco Carbonetti; Elsa Iannicelli; Giulia Anania; Barbara Imperatrice; A. Pellicelli; Gianfranco Delle Fave; Massimo Marignani
BACKGROUND Sarcopenia is a complication and independent risk factor for mortality in patients with liver cirrhosis. AIM To assess the prevalence and influence of sarcopenia on overall survival in a cohort of cirrhotic patients with hepatocellular carcinoma managed in a tertiary center. MATERIAL AND METHODS Abdominal computed tomography of 92 consecutive hepatocellular carcinoma cirrhotic patients, enrolled and followed from 2004 to 2014, were retrospectively studied with a software analyzing the cross-sectional areas of muscles at third lumbar vertebra level. Data was normalized for height, skeletal muscle index (SMI) calculated and presence of Sarcopenia measured. Sarcopenia was defined by SMI ≤ 41 cm2/m2 for women and ≤ 53 cm2/m2 for men with body mass index (BMI) ≥ 25, and ≤ 43 cm2/m2 for men and women with BMI < 25, respectively. RESULTS Median age at diagnosis was 71.9 years (30.7-86.4) and BMI 24.7 (17.5-36.7), comparable in women 23.1, (17.5-36.7) and men 24.7 (18.4-36.7). A class of CHILD score and BCLC A prevailed (55.4% and 41.3%, respectively); metastatic disease was found in 12% of cases. Sarcopenia was present in 40.2% of cases, mostly in females (62.9%; p = 0.005). Mean overall survival was reduced in sarcopenic patients, 66 (95% CI 47 to 84) vs. 123 (95% CI 98 to 150) weeks (p = 0.001). At multivariate analysis, sarcopenia was a predictor of reduced overall survival, independent of age (p = 0.0027). CONCLUSIONS This retrospective study shows high prevalence of sarcopenia among cirrhotic patients with hepatocellular carcinoma. Presence of sarcopenia was identified as independent predictor of reduced overall survival. As easily measurable by CT, sarcopenia should be determined for prognostic purposes in this patient population.
World Journal of Gastrointestinal Pathophysiology | 2014
Giulia Anania; Elia Gigante; Matteo Piciucchi; Emanuela Pilozzi; Eugenio Pucci; A. Pellicelli; Carlo Capotondi; Michele Rossi; F Baccini; Giulio Antonelli; Paola Begini; Gianfranco Delle Fave; Massimo Marignani
AIM To analyze the safety and the adequacy of a sample of liver biopsies (LB) obtained by gastroenterologist (G) and interventional radiologist (IR) teams. METHODS Medical records of consecutive patients evaluated at our GI unit from 01/01/2004 to 31/12/2010 for whom LB was considered necessary to diagnose and/or stage liver disease, both in the setting of day hospital and regular admission (RA) care, were retrieved and the data entered in a database. Patients were divided into two groups: one undergoing an ultrasonography (US)-assisted procedure by the G team and one undergoing US-guided biopsy by the IR team. For the first group, an intercostal approach (US-assisted) and a Menghini modified type needle 16 G (length 90 mm) were used. The IR team used a subcostal approach (US-guided) and a semiautomatic modified Menghini type needle 18 G (length 150 mm). All the biopsies were evaluated for appropriateness according to the current guidelines. The number of portal tracts present in each biopsy was assessed by a revision performed by a single pathologist unaware of the previous pathology report. Clinical, laboratory and demographic patient characteristics, the adverse events rate and the diagnostic adequacy of LB were analyzed. RESULTS During the study period, 226 patients, 126 males (56%) and 100 females (44%), underwent LB: 167 (74%) were carried out by the G team, whereas 59 (26%) by the IR team. LB was mostly performed in a day hospital setting by the G team, while IR completed more procedures on inpatients (P < 0.0001). The groups did not differ in median age, body mass index (BMI), presence of comorbidities and coagulation parameters. Complications occurred in 26 patients (16 G team vs 10 IR team, P = 0.15). Most gross samples obtained were considered suitable for basal histological evaluation, with no difference among the two teams (96.4% G team vs 91.5% IR, P = 0.16). However, the samples obtained by the G team had a higher mean number of portal tracts (G team 9.5 ± 4.8; range 1-29 vs IR team 7.8 ± 4.1; range 1-20) (P = 0.0192) and a longer mean length (G team 22 mm ± 8.8 vs IR team 15 ± 6.5 mm) (P = 0.0001). CONCLUSION LB can be performed with similar outcomes both by G and IR. Use of larger dimension needles allows obtaining better samples, with a similar rate of adverse events.
United European gastroenterology journal | 2018
Giulio Antonelli; Elia Gigante; M. Iavarone; Paola Begini; A. Sangiovanni; Elsa Iannicelli; Piero Biondetti; A. Pellicelli; Lucia Miglioresi; Paolo Marchetti; P. Lampertico; Massimo Marignani
Background Sarcopenia has been associated with poor outcomes in patients with cirrhosis and solid tumours. Objective Analyse the influence of sarcopenia on survival and treatment duration in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods We conducted a multicentre, retrospective study on 96 patients with advanced HCC treated with sorafenib, all with available abdominal computed tomography (CT) scan within 30 days from treatment start. Anthropometric, laboratory, treatment and follow-up data were collected. Sarcopenia was defined by reduced skeletal muscle index calculated from an L3 section CT image. Results Sarcopenia was present in 49% of patients. Patients were divided into two groups according to sarcopenia: age was significantly higher in the sarcopenic group (SG) (66 years (31–87) versus 72 years (30–84), p = 0.04], with no difference in other baseline characteristics. The SG showed shorter overall survival (OS) (39 (95% confidence interval (CI) 26–50) versus 61 (95% CI 47–77) weeks (p = 0,01)) and shorter time on treatment (12.3 (95% CI 8–19) versus 25.9 (95% CI 15–33) weeks (p = 0.0044)). At multivariate analysis, sarcopenia was independently associated to reduced OS (p = 0.03) and reduced time on treatment (p = 0.001). Conclusion Sarcopenia is present in almost half of patients with advanced HCC, and is associated with reduced survival and reduced duration of oral chemotherapy.
Scientific Reports | 2018
Giovanni Addolorato; Gabriele Angelo Vassallo; Giulio Antonelli; Mariangela Antonelli; Claudia Tarli; Antonio Mirijello; Adwoa Agyei-Nkansah; Maria Chiara Mentella; Daniele Ferrarese; Vincenzina Mora; Marco Barbara; Marcello Maida; Calogero Cammà; Antonio Gasbarrini
Binge drinking (BD) is a common pattern of alcohol consumption among adolescents. At present few data are available on the possible relationship between BD and alcohol use disorders (AUD) in adolescents. The aim of this study was to assess the prevalence of BD and relationship between BD behavior and AUD among adolescents. A total of 2704 students attending 10 purposively selected high schools from three Italian provinces were surveyed. Questionnaires regarding socio-demographic data, pattern and amount of alcohol intake, smoking habits, use of illicit drugs, and physical activity were administered. AUD and affective disorders were also evaluated. Alcohol intake was reported by 2126 participants; 1278 reported at least one episode BD in the last year and 715 in the last month. A diagnosis of AUD was made in 165 adolescents. The prevalence of AUD was higher in adolescents that reported BD behavior than in those that did not report BD (11.6% vs 0.9%, respectively; p < 0.0001). Logistic regression showed a positive relationship between a diagnosis of AUD and BD behavior (OR 9.6; 95% CI 4.7–22·9; p < 0.0001). In conclusion alcohol consumption with the pattern of BD among adolescents is highly related to development of AUD.
Scientific Reports | 2018
Giovanni Addolorato; Gabriele Angelo Vassallo; Giulio Antonelli; Mariangela Antonelli; Claudia Tarli; Antonio Mirijello; Adwoa Agyei-Nkansah; Maria Chiara Mentella; Daniele Ferrarese; Vincenzina Mora; Marco Barbara; Marcello Maida; Calogero Cammà; Antonio Gasbarrini
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
Digestive and Liver Disease | 2015
Elia Gigante; Giulio Antonelli; Paola Begini; Francesco Carbonetti; Elsa Iannicelli; Paolo Marchetti; L. Miglioresi; A. Pellicelli; G. Delle Fave; Massimo Marignani
P0367 SARCOPENIA IS ASSOCIATED WITH A REDUCED SURVIVAL IN PATIENTS WITH HEPATOCARCINOMA UNDERGOING SORAFENIB TREATMENT E. Gigante, G. Antonelli, P. Begini, F. Carbonetti, E. Iannicelli, P. Marchetti, A. Pellicelli, L. Miglioresi, G. Delle Fave, M. Marignani. Digestive and Liver Diseases unit, Radiology unit, Oncology unit, St. Andrea Hospital, Faculty of Medicine and Psychology, University ’Sapienza’, Liver Unit, San Camillo Forlanini Hospital, Rome, Italy E-mail: [email protected]
Radiologia Medica | 2016
Francesco Carbonetti; Antonio Cremona; Valentina Carusi; Marco Guidi; Elsa Iannicelli; Marco Di Girolamo; Daniela Sergi; Alvise Clarioni; Giulio Baio; Giulio Antonelli; Luca Fratini; Vincenzo David
Journal of Hepatology | 2018
Giulio Antonelli; Elia Gigante; M. Iavarone; Paola Begini; P. Biondetti; A. Pellicelli; A. Sangiovanni; P. Lampertico; Massimo Marignani
Digestive and Liver Disease | 2018
Giulio Antonelli; Elia Gigante; M. Iavarone; Paola Begini; A. Sangiovanni; Elsa Iannicelli; P. Biondetti; A. Pellicelli; Lucia Miglioresi; Paolo Marchetti; P. Lampertico; Massimo Marignani
Journal of Hepatology | 2015
Elia Gigante; Giulio Antonelli; Paola Begini; Francesco Carbonetti; Elsa Iannicelli; Paolo Marchetti; A. Pellicelli; L. Miglioresi; G. Delle Fave; Massimo Marignani
Collaboration
Dive into the Giulio Antonelli's collaboration.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
View shared research outputs